GlassScriptPhysician profile
Amanda G Deasy
NPI 1912324708
$5,383.85
in general payments reported to CMS, 2019-2025
30 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $115 · 2021: $185 · 2022: $1,007 · 2023: $1,106 · 2024: $1,412 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.10 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.05 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $644.76 | 2019 | |
| Alcon Vision LLC | $560.94 | 2020-2025 | Clareon, Centurion, Hydrus Microstent |
| Mallinckrodt Hospital Products INC. | $553.22 | 2022-2024 | Acthar |
| Sun Pharmaceutical Industries INC. | $302.55 | 2021-2025 | Cequa |
| Rayner Intraocular Lenses Limited | $272.86 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Glaukos Corporation | $261.29 | 2023-2025 | Idose, Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Ocular Therapeutix, INC. | $249.66 | 2021-2024 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $151.00 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $139.97 | 2022-2025 | Miebo, Lotemax Sm, Vyzulta |
| Harrow Eye, LLC | $134.50 | 2024-2025 | Iheezo, Vevye |
| Genentech USA, INC. | $126.00 | 2022 | |
| Rxsight INC | $117.46 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Allergan, INC. | $113.91 | 2020-2022 | |
| Genentech, INC. | $108.25 | 2023 | Vabysmo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $102.42 | 2022-2023 | |
| Oyster Point Pharma, INC. | $93.05 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $81.12 | 2021-2023 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $42.17 | 2019-2020 | |
| Alimera Sciences, INC. | $40.35 | 2022 | |
| Kala Pharmaceuticals, INC. | $31.00 | 2019-2020 | |
| Eyepoint US, INC. | $28.66 | 2021 | |
| Amgen INC. | $20.58 | 2024 | Tepezza |
| Thea Pharma INC. | $19.81 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $17.31 | 2020 | |
| Ivantis, INC | $16.66 | 2019 | |
| Horizon Therapeutics Plc | $15.27 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.02 | 2020 | |
| Oasis Medical, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Deasy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.